1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Concert’s CTP-543 Shows Advantages Over Lilly, Pfizer Candidates For Alopecia

 
• By Joseph Haas

Concert’s deuterated ruxolitinib analog is potentially third in line to market for alopecia areata, behind Lilly’s Olumiant and a Pfizer JAK3 inhibitor, but may be demonstrating a best-in-class profile.

Front view of a balding woman before and after hair treatment. Divided image of the head. Two halves. Sticker revealing healthy scalp. Female alopecia. Isolated vector illustration.
Concert is vying with Lilly and Pfizer in the unmet alopeic areata indication

On the heels of confirmation of its intellectual property over its JAK1/2 inhibitor CTP-543, Concert Pharmaceuticals, Inc. now has a successful Phase III study that could position it to have a best-in-class profile in alopecia areata. The drug is likely to reach market after big pharma rivals Eli Lilly and Company and Pfizer Inc., but the pivotal data indicate advantages that could help it catch up, according to analysts.

Concert announced on 23 May that CTP-543, a deuterated formulation of Lilly/Incyte Corporation’s JAK inhibitor Jakafi (ruxolitinib), met the primary endpoint of scalp-hair regrowth in alopecia patients with at least 50% hair loss in the 706-patient, placebo-controlled THRIVE-AA1 study. The Lexington, MA-based firm expects to report data from a second pivotal trial, THRIVE-AA2, during the third quarter and potentially submit a new drug application for CTP-543 during the first half of 2023

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.

More from R&D

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.